SCHEMBL5643266

SCHEMBL5643266

CN(C)CC1(c2ccc(N3CC(CNC(=O)c4ccc5cc(Cl)ccc5n4)CC3=O)cc2)CC1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.36
▸ SCN9A Q15858 1/20 0.35
▸ ATF4 P18848 1/20 0.34
▸ NAPEPLD Q6IQ20 2/20 0.34
▸ F10 P00742 2/20 0.34
▸ FPR2 P25090 1/20 0.34
▸ ENPP2 Q13822 3/20 0.33
▸ SLC6A4 P31645 3/20 0.33
▸ MALT1 Q9UDY8 2/20 0.33
▸ SLC6A2 P23975 1/20 0.33
▸ SLC6A3 Q01959 1/20 0.33
▸ METAP2 P50579 1/20 0.33
▸ NFKB1 P19838 1/20 0.33
▸ NFKB2 Q00653 1/20 0.33
▸ RELA Q04206 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5638279 0.87 LMNA (0.39) POLBF10SLC6A4SLC6A2SLC6A3
SCHEMBL5641220 0.87 ENPP2 (0.39) SCN9AF10FPR2ENPP2SLC6A4
SCHEMBL5642024 0.86 LMNA (0.37) POLBF10SLC6A4SLC6A2SLC6A3
SCHEMBL5640819 0.83 F10 (0.41) POLBF10ENPP2SLC6A4SLC6A2
SCHEMBL5640071 0.83 F10 (0.41) POLBF10ENPP2SLC6A4SLC6A2
SCHEMBL5639571 0.83 TP53 (0.46) POLBLMNATP53MAPT
SCHEMBL5640312 0.83 CNR1 (0.38) POLBF10FPR2ENPP2LMNA
SCHEMBL5639220 0.83 ALOX15 (0.44) F10
SCHEMBL5638730 0.83 HRH4 (0.47) —
SCHEMBL5639606 0.82 F10 (0.45) POLBF10SLC6A4SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7199149-B2 Monocyclic and bicyclic lactams as factor Xa inhibitors BRISTOL MYERS SQUIBB COMPANY (US) 2007-04-03 — — US disclosed
US-20050107361-A1 Monocyclic and bicyclic lactams as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMANY 2005-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107361-A1 Monocyclic and bicyclic lactams as factor Xa inhibitors F2, F12, SPINT2 POLB 4173/4885SCN9A 580/4885ATF4 2707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback